- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
PLAY BUTTON
PLAY BUTTON
8 Cards in this Set
- Front
- Back
|
Investigational new drug and New Drug Application
|
IND and NDA
|
|
PhRMA
|
Pharmaceutical Research and Manufacturers Association
|
|
Institutional Review Board
|
IRB
|
|
DTC
|
Direct-to-consumer (advertising)
|
|
Federal Drug Administration (FDA)
|
• Premarketing clearance of all new drug products
• Regulation of all labeling and advertising of Rx products • Regulation of manufacturing • Regulation of bioequivalence standards • Postmarketing surveillance |
|
Pink Sheet
|
Since 1939, this “Bible” of the prescription pharmaceutical industry has provided expert, in-depth analysis of regulatory, legislative, legal and business developments shaping the industry.
|
|
pre-clinical phase
|
n this clinical phase, studies are done in-vitro and in-vivo to obtain efficacy, toxicity, and pharmacokinetic information. This is done to determine whether or not the drug candidate is worth developing as an investigation new drug (IND)
|
|
Orphan Drug Act
|
This Act is meant to encourage pharmaceutical companies to develop drugs for diseases that have a small market. Companies that develop such a drug (a drug for a disorder affecting fewer than 200,000 people in the United States) may sell it without competition for seven years.
|
